GlassScriptPhysician profile
Lalith Uragoda
NPI 1366443483
$12,282.74
in general payments reported to CMS, 2019-2025
46 companies · $877 in 2025
The $877 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,386 · 2020: $1,179 · 2021: $1,263 · 2022: $5,654 · 2023: $1,238 · 2024: $685 · 2025: $877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,629.51 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,102.08 | 2019-2025 | Breztri, Fasenra, Imfinzi |
| Pulmonx Corporation | $956.23 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $708.17 | 2019-2025 | Ofev |
| Grifols USA, LLC | $584.67 | 2019-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $520.32 | 2019-2023 | Uptravi, Opsumit |
| Glaxosmithkline, LLC. | $475.93 | 2019-2022 | |
| Genzyme Corporation | $362.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.38 | 2019-2023 | Eliquis |
| United Therapeutics Corporation | $261.26 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Inspire Medical Systems, INC. | $226.48 | 2024 | Inspire |
| Genentech USA, INC. | $211.26 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.60 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $160.59 | 2019-2025 | Zerbaxa, Winrevair, Recarbrio |
| Novartis Pharmaceuticals Corporation | $157.75 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lalith Uragoda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.